by Nature Communications
Researchers say interleukin 4 (IL-4) is implicated in chimeric antigen receptor (CAR) T-cell exhaustion — a primary factor blocking durable response to CAR immunotherapy — and thus may...
by Nature
Adaptor chimeric antigen receptor (AdCAR) T-cell platforms may allow for better immune-targeting of acute myeloid leukemia (AML), according to researchers.
by AACR
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab (D-R) over lenalidomide alone (R) as post-transplant maintenance therapy for patients with newly diagnosed...
by ASTCT Advocacy Update
Mark your calendars for ASTCT's Government Relations Spotlight Session titled "Inside the Administration - Insight into the Federal Government and How We Can Make a Lasting Impact"...
by Alex Kadhim
Researchers at SickKids Hospital and McMaster University have developed a novel chimeric antigen receptor (CAR) T-cell therapy targeting ROBO1, a protein involved in axonal guidance, for the...
by Blood
Based on results from the OUTREACH study, outpatient monitoring appears to be both safe and effective for patients with relapsed/refractory large B-cell lymphoma who undergo lisocabtagene...